Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension

Core Insights - Idorsia Ltd has received marketing authorization from Swissmedic for JERAYGO (aprocitentan) to treat resistant hypertension in adults, marking it as the first and only endothelin receptor antagonist for this condition [1][8] - Resistant hypertension affects approximately 10% of hypertensive patients, highlighting the need for more effective treatment options [3] - JERAYGO has shown significant blood pressure reduction in diverse patient populations, including those with obesity, chronic kidney disease, or type 2 diabetes [4] Company Overview - Idorsia is focused on developing transformative medicines and has a strong scientific foundation, with JERAYGO representing their second product approval in Switzerland [4][15] - The company is in discussions with potential partners to expand the availability of JERAYGO across Switzerland and Europe [4] Product Details - JERAYGO is administered orally at a recommended starting dose of 12.5 mg once daily, which can be increased to 25 mg for patients needing tighter blood pressure control [1] - Aprocitentan, the active ingredient in JERAYGO, is a dual endothelin receptor antagonist that has been commercially available in the US as TRYVIO™ since October 2024 [12] Clinical Study Findings - The Phase 3 PRECISION study demonstrated that both 12.5 mg and 25 mg doses of aprocitentan significantly reduced sitting systolic blood pressure compared to placebo [10] - The treatment effect was consistent across various demographics, including age, sex, and race, and was evident within the first two weeks of treatment [10] Patient Demographics - The study included 730 patients with a mean age of 61.7 years, with a significant portion having comorbidities such as type 2 diabetes (54.1%) and chronic kidney disease (22.2%) [7][9] Safety Profile - Common adverse reactions to aprocitentan included edema/fluid retention and decreased hemoglobin levels, with specific contraindications for pregnant women and those with severe hepatic impairment [11]